• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov20
Mizuho and TD Cowen Maintain Buy Ratings for Iovance Biotherapeutics
20:22
Nov6
H.C. Wainwright and Barclays Analysts Reiterate Buy Rating on Iovance Biotherapeutics
16:23
Iovance Biotherapeutics released FY2025 9 Months Earnings on November 6 Pre-Market (EST), actual revenue USD 176.73 M, actual EPS USD -0.9442
14:30
Iovance Biotherapeutics released FY2025 Q3 earnings on November 6 Pre-Market EST, actual revenue USD 67.46 M (forecast USD 72.81 M), actual EPS USD -0.2506 (forecast USD -0.2642)
14:30
Nov4
Goonewardene rates Iovance Biotherapeutics as Strong Buy
14:24
Oct30
Iovance Biotherapeutics to Release FY2025 Q3 Earnings on November 6, Pre-Market EST; Forecast Revenue USD 74.48M, EPS USD -0.2642
00:42

Schedules & Filings

Schedules
Filings
Nov6
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 67.46 M, Net Income -91.25 M, EPS -0.2506

Aug7
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 59.95 M, Net Income -111.66 M, EPS -0.3337

May8
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 49.32 M, Net Income -116.16 M, EPS -0.3597

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
EKSO
10.580
+93.77%
+5.120
AEHL
2.180
+92.92%
+1.050
AFJK
82.580
+89.19%
+38.930
PFSA
0.1218
+78.33%
+0.053
DLXY
1.410
+67.86%
+0.570
ULY
2.760
+52.49%
+0.950
MENS
4.220
+51.80%
+1.440
CETX
2.980
+41.23%
+0.870
DAIC
0.5500
+39.06%
+0.154
ONTF
8.060
+37.54%
+2.200
View More